an Abbreviated New Drug Application (ANDA) in June 2014. This is the second product from Beximco Pharma to be approved by the US FDA after Carvedilol, a prescript...
BPL receives 2nd US FDA product approval
Beximco Pharmaceuticals Limited ("BPL" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, has received US Food and Drug Administration (FDA) approval for Sotalol Hydrochloride, a generic version of the cardiovascular drug Betapace, following submission of
an Abbreviated New Drug Application (ANDA) in June 2014. This is the second product from Beximco Pharma to be approved by the US FDA after Carvedilol, a prescript...
an Abbreviated New Drug Application (ANDA) in June 2014. This is the second product from Beximco Pharma to be approved by the US FDA after Carvedilol, a prescript...



















